Zymergen (ZY) Set to Announce Earnings on Thursday

Zymergen (NASDAQ:ZY – Get Rating) will be releasing its earnings data after the market closes on Thursday, May 12th. Analysts expect Zymergen to post earnings of ($0.71) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Zymergen (NASDAQ:ZY – Get Rating) last issued its quarterly earnings data on Tuesday, March 22nd. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.83) by $0.13. The company had revenue of $3.04 million during the quarter, compared to analysts’ expectations of $2.83 million. Zymergen had a negative return on equity of 213.99% and a negative net margin of 2,160.81%. On average, analysts expect Zymergen to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of NASDAQ ZY opened at $1.76 on Thursday. The stock has a market cap of $181.50 million and a PE ratio of -0.18. The business has a fifty day moving average of $2.77 and a two-hundred day moving average of $5.78. Zymergen has a 52-week low of $1.54 and a 52-week high of $47.95.

A number of research analysts have issued reports on ZY shares. The Goldman Sachs Group cut their price objective on Zymergen from $6.00 to $4.00 and set a “neutral” rating for the company in a report on Wednesday, April 13th. William Blair reissued a “market perform” rating on shares of Zymergen in a report on Wednesday, March 9th. HSBC upgraded Zymergen from a “reduce” rating to a “hold” rating and set a $6.50 target price for the company in a research note on Wednesday, January 12th. UBS Group lowered their target price on Zymergen from $13.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, March 24th. Finally, Zacks Investment Research upgraded Zymergen from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a research note on Saturday, January 8th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $6.89.

In related news, CTO Aaron Kimball sold 32,639 shares of Zymergen stock in a transaction dated Friday, April 1st. The stock was sold at an average price of $2.87, for a total value of $93,673.93. Following the completion of the sale, the chief technology officer now directly owns 712,644 shares in the company, valued at $2,045,288.28. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 48,015 shares of company stock valued at $150,032.

Hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada boosted its holdings in Zymergen by 99.9% during the third quarter. Royal Bank of Canada now owns 2,561 shares of the company’s stock worth $34,000 after buying an additional 1,280 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Zymergen by 323.1% during the 4th quarter. Legal & General Group Plc now owns 6,715 shares of the company’s stock valued at $45,000 after purchasing an additional 5,128 shares in the last quarter. Amalgamated Bank bought a new position in shares of Zymergen during the 4th quarter valued at about $72,000. Squarepoint Ops LLC bought a new position in shares of Zymergen during the 4th quarter valued at about $81,000. Finally, Alliancebernstein L.P. bought a new position in shares of Zymergen during the 4th quarter valued at about $98,000. Hedge funds and other institutional investors own 68.40% of the company’s stock.

About Zymergen (Get Rating)

Zymergen Inc design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems.

Featured Articles